Browse
Explore conditions, clinical trials, and the organisations running them.
Never miss a new study
Get alerted when new trials match your condition
Sign up free to track the conditions you care about and get a personal digest when new trials appear.
By submitting, you agree to our Terms of use
127005 trials found · Page 84 of 6351
-
Could a clotting protein be the first treatment for bleeding stroke?
Disease control Recruiting nowThe objective of the rFVIIa for Acute Hemorrhagic Stroke Administered at Earliest Time (FASTEST) Trial is to establish the first treatment for acute spontaneous intracerebral hemorrhage (ICH) within a time window and subgroup of patients that is most likely to benefit. The centra…
Phase 3 • Sponsor: Joseph Broderick, MD • Aim: Disease control
Last updated Aug 22, 2026 00:00 UTC
-
Could new immune drugs replace transplants for leukemia patients?
Disease control Recruiting nowAdult acute lymphoblastic leukemia (ALL) includes Ph-positive (Phpos) ALL, Ph-negative (Phneg) B-cell precursor (BCP) ALL and T-ALL/lymphoblastic lymphoma (LL), accounting for approximately 25, 50 and 25% of all cases, respectively. In younger adults, the results associated with …
Phase 2/3 • Sponsor: Assistance Publique - Hôpitaux de Paris • Aim: Disease control
Last updated Jun 27, 2026 09:03 UTC
-
Could a One-Time cell therapy ease myasthenia gravis? new trial launches
Disease control OngoingThe AURORA Study is evaluating the safety, tolerability, and efficacy of an investigational mRNA CAR T-cell therapy known as Descartes-08 in adults with acetylcholine receptor autoantibody -positive generalized myasthenia gravis. Part 1 of the study will last around 6 months. For…
Phase 3 • Sponsor: Cartesian Therapeutics • Aim: Disease control
Last updated Sep 03, 2026 00:00 UTC
-
Can a targeted pill boost standard therapy for hard-to-treat leukemia?
Disease control Recruiting nowTreatment of patients with newly diagnosed AML who are not eligible for intensive chemotherapy has remained an area of high unmet medical need. The combination therapy with two medicines, azacitidine and venetoclax, is the usual plan of action. This has brought significant progre…
Phase 3 • Sponsor: Stichting Hemato-Oncologie voor Volwassenen Nederland • Aim: Disease control
Last updated Sep 04, 2026 00:00 UTC
-
Can a different immune drug cut viral infections after stem cell transplants?
Disease control Recruiting nowAllogeneic hematopoietic stem cell transplantation is the only curative treatment for malignant hematologic diseases. However, immune rejection is a major limitation in its application. In the "Beijing Protocol", the use of granulocyte colony-stimulating factor (G-CSF) in combina…
Phase 2/3 • Sponsor: Peking University First Hospital • Aim: Disease control
Last updated Aug 07, 2026 00:00 UTC
-
Massive west african trial takes on deadly lassa fever with new drug cocktail
Disease control Recruiting nowLassa fever (LF) is a viral haemorrhagic fever responsible of 5000 deaths per year in West Africa, with in-hospital mortality at 12%. Transmission to humans occurs mainly via direct or indirect exposure to excreta from the rodent reservoir, mainly made up of Mastomys natalensis .…
Phase 2/3 • Sponsor: Irrua Specialist Teaching Hospital • Aim: Disease control
Last updated Jun 27, 2026 09:01 UTC
-
Engineered immune cells take on tough blood cancers
Disease control Stopped earlyThe study will evaluate safety and efficacy of a 4th generation chimeric antigen receptor gene-modified T cells targeting CD19 (4SCAR19) for patients with B cell malignancies. Clinical response and development of a standardized lentiviral vector and cell production protocol will …
Sponsor: Shenzhen Geno-Immune Medical Institute • Aim: Disease control
Last updated Aug 26, 2026 00:00 UTC
-
New combo therapy offers hope for tough leukemia cases
Disease control OngoingThis prospective multicenter study evaluates the efficacy and safety of PD-1 inhibitor combined with venetoclax and HAG/CAG chemotherapy in refractory/relapsed T-ALL (R/R T-ALL). Despite standard chemotherapy, R/R T-ALL remains challenging, with low salvage remission rates (\~40%…
Phase 3 • Sponsor: Fujian Medical University Union Hospital • Aim: Disease control
Last updated Jun 27, 2026 12:23 UTC
-
Engineered immune cells take on tough T-Cell cancers in early trial
Disease control Recruiting nowThis will be a Phase 1, open-label study to evaluate the safety and efficacy of BEAM-201 in patients with R/R T-ALL or T-LLy. BEAM-201 is an allogeneic anti-CD7 CART therapy.
Phase 1 • Sponsor: Stephan Grupp MD PhD • Aim: Disease control
Last updated Jul 09, 2026 00:00 UTC
-
Own skin cells turned brain cells: a new hope for Parkinson's?
Disease control Recruiting nowThe goal of this clinical trial is to assess the safety and tolerability of the surgical transplantation of dopaminergic progenitor cells into the brains of participants with Parkinson's disease. The transplanted dopaminergic cells will be derived from the participant's own skin …
Phase 1 • Sponsor: Jeffrey S. Schweitzer, MD, PhD • Aim: Disease control
Last updated Jun 27, 2026 12:00 UTC
-
Can a Three-Pronged attack shrink untreatable liver tumors?
Disease control Recruiting nowTo evaluate the efficacy and safety of anlotinib combined with benmelstobart and HAIC as first-line treatment for unresectable hepatocellular carcinoma.
Phase 2 • Sponsor: Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University • Aim: Disease control
Last updated Sep 10, 2026 00:00 UTC
-
Double shocks: could two defibrillators save more cardiac arrest patients?
Disease control Recruiting nowDouble Sequential External Defibrillation (DSED) represents an alternative treatment of refractory ventricular fibrillation (rVF) in out-of-hospital cardiac arrest (OHCA). The procedure consists of two defibrillators that administer shocks at the same time. Currently, the proced…
Sponsor: St. Olavs Hospital • Aim: Disease control
Last updated Jul 23, 2026 00:00 UTC
-
New drug duo aims to tackle aggressive bladder cancer
Disease control Recruiting nowIn phase II, the main objective is to evaluate the efficacy of SHR-A2102 combined with Adebrelimab in the treatment of muscular invasive bladder cancer (MIBC); The main objective of phase III is to evaluate the efficacy of SHR-A2102 for injection combined with Adebrelimab compare…
Phase 2/3 • Sponsor: Suzhou Suncadia Biopharmaceuticals Co., Ltd. • Aim: Disease control
Last updated Jul 15, 2026 00:00 UTC
-
New hope for KRAS lung cancer: targeted combo enters phase 3 trial
Disease control Recruiting nowThis is a trial to evaluate the efficacy, safety, and tolerability of adagrasib plus pembrolizumab plus platinum-doublet chemotherapy versus placebo plus pembrolizumab plus platinum-doublet chemotherapy in participants with previously untreated, locally advanced or metastatic NSC…
Phase 3 • Sponsor: Mirati Therapeutics Inc. • Aim: Disease control
Last updated Sep 03, 2026 00:00 UTC
-
Engineered immune cells take aim at Hard-to-Treat lupus
Disease control Recruiting nowThis is a Phase 1b/2, single-arm, open-label, multi-center, clinical study of AZD0120, a CD19/BCMA dual CAR T cell therapy, to evaluate the safety, tolerability, and efficacy in adult participants with refractory Systemic Lupus Erythematosus.
Phase 1/2 • Sponsor: AstraZeneca • Aim: Disease control
Last updated Aug 14, 2026 00:00 UTC
-
Engineered immune cells take on lupus, scleroderma, and Sjogren's
Disease control Recruiting nowThis is a single-center, open-label, non-randomized, single-arm clinical trial. Patients with refractory lupus neritis (SLE-LN), systemic sclerosis (SSc), primary Sjogren syndrome combined with pulmonary artery hypertension (pSS-PAH) and other autoimmune diseases (AID) receive CD…
Phase 1/2 • Sponsor: Beijing GoBroad Hospital • Aim: Disease control
Last updated Aug 01, 2026 00:00 UTC
-
New marburg vaccine trial aims to stop deadly virus
Vaccine OngoingA Phase 2, Randomized, Double-blind, Placebo-Controlled Trial to Evaluate Safety, Tolerability, and Immune Responses of an Investigational Monovalent Chimpanzee Adenoviral Vectored Marburg Virus Vaccine in Healthy Adults
Phase 2 • Sponsor: Albert B. Sabin Vaccine Institute • Aim: Vaccine
Last updated Jun 27, 2026 08:14 UTC
-
Could a One-Time gene fix free thalassemia patients from lifelong transfusions?
Disease control Recruiting nowThe main goal of this study is to find out if the blood disorder called transfusion-dependent beta thalassemia can be safely treated by modifying blood stem cells. This is done by collecting blood stem cells from the subject, modifying those cells, adding a healthy beta globin ge…
Phase 1/2 • Sponsor: Children's Hospital of Philadelphia • Aim: Disease control
Last updated Jun 27, 2026 12:08 UTC
-
Can a daily pill help shed pounds? a new trial puts HRS-7535 to the test.
Disease control CompletedThe study is being conducted to evaluate the efficacy and safety of HRS-7535 in subjects with overweight or obesity.
Phase 3 • Sponsor: Shandong Suncadia Medicine Co., Ltd. • Aim: Disease control
Last updated Jul 29, 2026 00:00 UTC
-
New lung cancer drug rilvegostomig takes on keytruda in global showdown
Disease control Recruiting nowThe purpose of ARTEMIDE-Lung04 is to assess the efficacy and safety of rilvegostomig compared with pembrolizumab monotherapy as 1L treatment in participants with mNSCLC and whose tumors express PD-L1.
Phase 3 • Sponsor: AstraZeneca • Aim: Disease control
Last updated Aug 05, 2026 00:00 UTC